GSK699

GSK699 is a PCAF/GCN5 PROTAC degrader. GSK699 promotes the ubiquitination and degradation of PCAF/GCN5. GSK699 inhibits the production of cytokines/chemokines (e.g., IL-6, CXCL1/GROα) . GSK699 can be used in the research of inflammatory diseases (target protein ligand: HY-101027, CRBN ligand: HY-103596) [1][2].

Product Specifications

CAS Number

[2260944-68-9]

UNSPSC

12352005

Target

CXCR; Histone Acetyltransferase; Interleukin Related

Related Pathways

Epigenetics; GPCR/G Protein; Immunology/Inflammation

Field of Research

Inflammation/Immunology

Smiles

O=C(N(CCCN(C1=CC=C(CCCOC2=CC=CC(C(N3C(CC4)C(NC4=O)=O)=O)=C2C3=O)C=C1)C)C)C5=CC=C([C@@H]6CN(C)C[C@H](NC(C=NN7C)=C(Br)C7=O)C6)C=C5

Molecular Formula

C45H51BrN8O7

Molecular Weight

895.84

References & Citations

[1]Bassi ZI, et al. Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. ACS Chem Biol. 2018 Oct 19;13 (10) :2862-2867. |[2]Luo H, et al. Advancing Design Strategy of PROTACs for Cancer Therapy. MedComm (2020) . 2025 Jun 25;6 (7) :e70258.